Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Laser showdown: where to zap the iris for better glaucoma control?

NCT ID NCT07195370

Disease control Sponsor: Isfahan University of Medical Sciences Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests two different spots (temporal vs inferior) for a YAG laser iridotomy in people with angle-closure glaucoma. Each patient gets one spot in each eye, and doctors track pressure, symptoms, and complications over six months. The goal is to find which location is safer and more effective at lowering eye pressure.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
YAG laser peripheral iridotomy (a procedure using a laser to create a small hole in the iris to improve fluid drainage)
What this could lead to
If successful, this could identify the best location for the laser procedure, potentially reducing complications and improving pressure control in glaucoma patients.
What could go wrong
This is a small, early-stage study with only 150 participants, and results may not apply to all patients. The procedure itself carries risks like bleeding or infection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 150 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2025

Expected to finish

Jan 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

24 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria:Diagnosis of Primary Angle-Closure Glaucoma. Adults (typically over 40 years old). Ability to provide informed consent. Narrow or closed anterior chamber angle (based on gonioscopy). Intraocular pressure (IOP) controlled with medication but requiring surgery. No previous iridotomy. Exclusion Criteria:econdary glaucoma. Active eye diseases (e.g., infection or inflammation). Advanced cataracts or lens-related issues. Severe visual impairment (e.g., less than 20/200 vision). Uncontrolled systemic diseases (e.g., diabetes or cardiovascular disease). Pregnancy or breastfeeding. Previous eye surgery (except for minor procedures). Inability to follow-up with scheduled visits. \-

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Angle-closure glaucoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

angle-closure glaucoma glaucoma primary angle-closure glaucoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Angle-closure glaucoma Glaucoma eye

Contacts and locations

Locations

  • Isfahan University of Medical Sciences

    Isfahan, Isfahan, 0098, Iran

More trials for these conditions

Other studies related to the condition(s) this trial covers.